Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 2)

NCT05836779 is registered in ClinicalTrials.gov with Caliway Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05836779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05836779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of CBL-514 Injection for the Treatment of Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite (Stage 2)
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 10, 2023
Completion date
January 5, 2024
Enrollment
23 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cellulite